Vera Therapeutics received accelerated FDA approval for its lead product, TRUTAKNA, in July 2026 and began recording limited product revenue. The company remains in a net loss position as it scales commercialization efforts and continues clinical development for other indications and product candidates.
Vera Therapeutics reported its first quarter of commercial revenue following the July 2026 FDA accelerated approval of TRUTAKNA, generating $10.3 million in net product revenue. The company also completed its sBLA submission for full FDA approval and presented positive two-year Phase 3 ORIGIN data demonstrating a 76% reduction in kidney disease progression risk.
Term
Q3 2026
“We are excited by the early momentum of the TRUTAKNA launch, which exemplifies our long-standing confidence in its potential to become a foundational therapy in IgAN. Our transition to a commercial-stage company marks a new chapter for Vera, as we deliver on our commitment to people living with IgAN.”
Marshall Fordyce, M.D., Founder and Chief Executive Officer
“Our team is executing on the launch priorities we established for TRUTAKNA, with growing interest from the IgAN community and approximately 700 PSFs received since launch. We are encouraged by the payer coverage policies taking shape. Our focus remains on expanding access and ensuring nephrologists have the tools and education they need to help eligible patients begin treatment with TRUTAKNA.”
Vera Therapeutics announced positive topline results from the final efficacy analysis of its Phase 3 ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in patients with IgA nephropathy. The trial met all prespecified endpoints, demonstrating a 76% reduction in the risk of kidney disease progression and stabilization of kidney function (eGFR) through 104 weeks. The company plans to submit a supplemental BLA for full FDA approval in the fourth quarter of 2026.